HEALTHglobal
Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral - Fierce Biotech
Single source
Updated 3 hours ago
First seen March 20, 2026 20:40:04Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral Fierce Biotech